271 related articles for article (PubMed ID: 35758021)
1. Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer.
Sun X; Xin S; Jin L; Zhang Y; Ye L
Bioengineered; 2022 May; 13(5):13986-13999. PubMed ID: 35758021
[TBL] [Abstract][Full Text] [Related]
2. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis Identified ETV7 as a Potential Prognostic Biomarker in Bladder Cancer.
Li H; Zhang Y; Zheng S
Biomed Res Int; 2021; 2021():8530186. PubMed ID: 34926692
[TBL] [Abstract][Full Text] [Related]
4. Increased Expression of NXPH4 Correlates with Immune Cell Infiltration and Unfavorable Prognosis in Hepatocellular Carcinoma.
Tang Q; Chen YM; Shen MM; Dai W; Liang H; Liu JN; Gao J
J Oncol; 2022; 2022():5005747. PubMed ID: 36245978
[TBL] [Abstract][Full Text] [Related]
5. Identification of Prognosis-Related Genes in Bladder Cancer Microenvironment across TCGA Database.
Zhao X; Tang Y; Ren H; Lei Y
Biomed Res Int; 2020; 2020():9143695. PubMed ID: 33204728
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitination-Related Molecular Subtypes and a Novel Prognostic Index for Bladder Cancer Patients.
Cai H; Chen H; Huang Q; Zhu JM; Ke ZB; Lin YZ; Zheng QS; Wei Y; Xu N; Xue XY
Pathol Oncol Res; 2021; 27():1609941. PubMed ID: 34776794
[No Abstract] [Full Text] [Related]
7. A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Zhong XY; Zeng N; Ma SY; He HD; Zhang ZB; Wang SG; Xia QD
Front Immunol; 2022; 13():908068. PubMed ID: 35898492
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.
Liu L; Hu J; Wang Y; Sun T; Zhou X; Li X; Ma F
Aging (Albany NY); 2020 Jun; 12(12):11967-11989. PubMed ID: 32570217
[TBL] [Abstract][Full Text] [Related]
9. Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response.
Xu W; Anwaier A; Ma C; Liu W; Tian X; Palihati M; Hu X; Qu Y; Zhang H; Ye D
Ann Med; 2021 Dec; 53(1):596-610. PubMed ID: 33830879
[TBL] [Abstract][Full Text] [Related]
10. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
11. Cytoskeleton regulator RNA expression on cancer-associated fibroblasts is associated with prognosis and immunotherapy response in bladder cancer.
Wu Y; Xu Y; He S; Li Y; Feng N; Fan J; Gong Y; Li X; Zhou L
Heliyon; 2023 Mar; 9(3):e13707. PubMed ID: 36873531
[TBL] [Abstract][Full Text] [Related]
12. Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer.
Huang Z; Yan Y; Wang T; Wang Z; Cai J; Cao X; Yang C; Zhang F; Wu G; Shen B
J Transl Med; 2022 Jul; 20(1):315. PubMed ID: 35836227
[TBL] [Abstract][Full Text] [Related]
13. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
14. Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1.
Zhao J; Shi L; Zeng S; Ma C; Xu W; Zhang Z; Liu Q; Zhang P; Sun Y; Xu C
Urol Oncol; 2018 Jun; 36(6):311.e1-311.e13. PubMed ID: 29602637
[TBL] [Abstract][Full Text] [Related]
15. PVT1 is a prognostic marker associated with immune invasion of bladder urothelial carcinoma.
Li P; Qiao G; Lu J; Ji W; Gao C; Qi F
Math Biosci Eng; 2022 Jan; 19(1):169-190. PubMed ID: 34902986
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
[TBL] [Abstract][Full Text] [Related]
17. A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer.
Wang W; Zhang X; Jiang S; Xu P; Chen K; Li K; Wang F; Le X; Zhang K
Front Immunol; 2023; 14():1187286. PubMed ID: 37691944
[TBL] [Abstract][Full Text] [Related]
18. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Analysis of Differentially Expressed DNA Damage Repair Genes in Bladder Cancer.
Yang Y; Yu J; Xiong Y; Xiao J; Dai D; Zhang F
Pathol Oncol Res; 2022; 28():1610267. PubMed ID: 35685866
[TBL] [Abstract][Full Text] [Related]
20. An innovative model based on N7-methylguanosine-related lncRNAs for forecasting prognosis and tumor immune landscape in bladder cancer.
Ren L; Yang X; Liu J; Wang W; Liu Z; Lin Q; Huang B; Pan J; Mao X
Cancer Cell Int; 2023 May; 23(1):85. PubMed ID: 37158958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
